Welcome to our dedicated page for Sophia Genetics Sa news (Ticker: SOPH), a resource for investors and traders seeking the latest updates and insights on Sophia Genetics Sa stock.
SOPHiA GENETICS SA (Nasdaq: SOPH) is frequently featured in news coverage as a cloud-native healthcare technology and AI company focused on precision medicine. News about SOPHiA GENETICS often centers on its SOPHiA DDM™ Platform, an AI-powered analytics environment that analyzes complex genomic and multimodal data to generate real-time, actionable insights for hospitals, laboratories, and biopharma institutions.
On this news page, readers can follow company announcements related to financial results, platform usage, and strategic direction. Recent press releases have discussed quarterly and preliminary full-year financial performance, including revenue trends, analysis volumes on SOPHiA DDM™, and guidance updates, as well as commentary from management on growth, operating leverage, and non-IFRS metrics.
Another major category of SOPH news involves collaborations and partnerships. SOPHiA GENETICS regularly announces agreements with cancer centers, academic institutions, sequencing technology providers, and biopharma companies. Examples include collaborations to co-develop next-generation sequencing oncology tests, integrate MSK-IMPACT® and MSK-ACCESS® assays powered with SOPHiA DDM™ on external sequencing platforms, and expand access to liquid biopsy and companion diagnostics in specific markets such as Japan.
Product and technology updates also feature prominently. The company has announced the launch of SOPHiA DDM™ Digital Twins, an AI-powered research technology that creates virtual representations of patients to simulate potential outcomes in oncology. Additional news highlights include partnerships that integrate SOPHiA DDM™ with sequencing systems to create streamlined, end-to-end workflows for next-generation sequencing and precision oncology research.
Investors, clinicians, and researchers who follow SOPH news can use this page to track developments in AI-driven precision medicine, including new applications on the SOPHiA DDM™ Platform, expansions of its global customer network, and collaborations aimed at advancing cancer and rare disease research.
SOPHiA GENETICS (Nasdaq: SOPH) will release first quarter 2026 financial results before U.S. markets open on Tuesday, May 5, 2026. A conference call to discuss results and business outlook begins at 8:00 a.m. EDT / 2:00 p.m. CET and will be webcast live.
A replay of the webcast will be available on the company's investor relations website after the call.
SOPHiA GENETICS (NASDAQ: SOPH) announced a collaboration with the Mount Sinai Health System to adopt the AI-powered SOPHiA DDM™ Platform for blood cancers and solid tumors to strengthen NGS testing and genomic interpretation.
Mount Sinai will use the platform to reduce manual analysis time, improve turnaround, and scale interpretation across complex genomic datasets; Mount Sinai treats over 4,000 oncology patients annually. The announcement was made at AACR 2026.
SOPHiA GENETICS (Nasdaq: SOPH) reported Q4 2025 revenue of $21.7M (+22% YoY) and full-year 2025 revenue of $77.3M (+19% YoY). Adjusted gross margin expanded to 74.2% in 2025. IFRS net loss was $79.0M for 2025; adjusted EBITDA loss was $41.5M. The company reaffirmed 2026 guidance of $92M–$94M revenue and adjusted EBITDA loss of $29M–$32M, and expects adjusted EBITDA breakeven around end-2026 and positive adjusted EBITDA in H2 2027.
SOPHiA GENETICS (Nasdaq:SOPH) announced leadership will present at TD Cowen's 46th Annual Health Care Conference in Boston.
Jurgi Camblong, CEO and co-founder, and Ross Muken, President, will participate in a fireside chat on March 4, 2026 at 10:30 am EST / 4:30 pm CET. According to the company, a live audio webcast will be available and a replay will be accessible for 90 days after the event.
SOPHiA GENETICS (Nasdaq: SOPH) will release fourth-quarter and full-year 2025 financial results before U.S. markets open on March 3, 2026. A conference call to discuss results and business outlook will begin at 8:00 AM EDT / 2:00 PM CET and will be webcast on the company investor relations website. A replay will be available after the call.
SOPHiA GENETICS (NASDAQ: SOPH) announced the addition of two major U.S. integrated health systems to its network, expanding use of the AI-native, cloud-based SOPHiA DDM™ across West Coast and Midwest laboratories.
The institutions will initially launch genomic testing for up to 60,000 patients annually, use Enhanced Exome for analysis of over 20,000 genes, and together serve a combined population of nearly one million cancer and rare disorder patients.
Summary not available.
Axalta (NYSE:AXTA) announced it won six Business Intelligence Group (BIG) Innovation Awards for product innovations across Refinish, Mobility Coatings, and Industrial Coatings on January 15, 2026. Honored products include a waterborne clearcoat that reduces solvent emissions by >65%, a low-bake OEM coatings system modeled to cut plant energy use by up to 40% and save up to $40M annually in maintenance for a 100,000-vehicle plant, and a clearcoat curing at 80°C that may lower CO2 per vehicle by ~16 kg (~20%). Other winners address EV battery fire resistance, 100% solids UV cabinet coating with zero VOCs, and electrical steel coating for high-speed motor bonding.
SOPHiA GENETICS (Nasdaq: SOPH) provided preliminary unaudited Q4 and full‑year 2025 results, issued 2026 guidance, and announced an executive transition plan.
Q4 2025: revenue of at least $21 million (+~20% YoY) and >105,000 analyses (+16% YoY). FY 2025: revenue of ~ $77 million (+~18% YoY) and a company record >391,000 analyses. FY 2026 guidance: revenue $92–94 million (~20–22% growth) and adjusted EBITDA loss $29–32 million. Leadership changes: Ross Muken promoted to CEO effective July 1, 2026; co‑founder Jurgi Camblong to transition to Executive Chairman (subject to election in June 2026). Results are preliminary and unaudited; final results expected on the March 3, 2026 earnings call.
SOPHiA GENETICS (NASDAQ: SOPH) and MD Anderson announced a strategic collaboration on January 7, 2026, to combine SOPHiA's AI analytics with MD Anderson's clinical expertise to accelerate AI-driven precision oncology.
The partners will co-develop an advanced next-generation sequencing oncology test built on the SOPHiA DDM™ Platform, create bioinformatics pipelines to interpret complex RNA-sequencing data, and launch R&D programs to track tumor evolution, improve genomic-test reproducibility, and match patients to clinical trials.